AVLSA
THRD
Atlas Venture Life Science Advisors’s Third Harmonic Bio THRD Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.5M | Hold |
10,402,286
| – | – | 8.53% | 5 |
|
|
2025
Q1 | $36.1M | Hold |
10,402,286
| – | – | 6.92% | 6 |
|
|
2024
Q4 | $107M | Sell |
10,402,286
-505,573
| -5% | -$5.2M | 13.06% | 4 |
|
|
2024
Q3 | $148M | Hold |
10,907,859
| – | – | 13.7% | 3 |
|
|
2024
Q2 | $142M | Hold |
10,907,859
| – | – | 14.93% | 3 |
|
|
2024
Q1 | $103M | Hold |
10,907,859
| – | – | 9.5% | 5 |
|
|
2023
Q4 | $120M | Hold |
10,907,859
| – | – | 14.25% | 4 |
|
|
2023
Q3 | $69.7M | Hold |
10,907,859
| – | – | 10.8% | 5 |
|
|
2023
Q2 | $52.5M | Hold |
10,907,859
| – | – | 6.53% | 6 |
|
|
2023
Q1 | $44.9M | Hold |
10,907,859
| – | – | 6.08% | 6 |
|
|
2022
Q4 | $46.9M | Hold |
10,907,859
| – | – | 5.65% | 8 |
|
|
2022
Q3 | $207M | Buy |
+10,907,859
| New | +$207M | 22.84% | 1 |
|